Precipio (NASDAQ:PRPO) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen downgraded shares of Precipio (NASDAQ:PRPO) from a buy rating to a hold rating in a research note released on Sunday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Precipio in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Precipio presently has a consensus rating of “Sell”.

Precipio Stock Performance

NASDAQ PRPO opened at $27.88 on Friday. Precipio has a fifty-two week low of $3.90 and a fifty-two week high of $29.53. The stock has a market cap of $48.85 million, a price-to-earnings ratio of -34.00 and a beta of 1.22. The business has a fifty day moving average of $24.65 and a 200-day moving average of $22.48. The company has a quick ratio of 1.10, a current ratio of 1.27 and a debt-to-equity ratio of 0.06.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PRPO. Geode Capital Management LLC lifted its stake in shares of Precipio by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 789 shares during the period. Renaissance Technologies LLC grew its position in shares of Precipio by 10.7% in the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock valued at $333,000 after purchasing an additional 1,400 shares during the period. Susquehanna International Group LLP purchased a new stake in shares of Precipio in the third quarter valued at $194,000. Evernest Financial Advisors LLC acquired a new position in Precipio in the third quarter valued at $374,000. Finally, Topline Capital Management LLC acquired a new position in Precipio in the third quarter valued at $1,158,000. 10.45% of the stock is currently owned by institutional investors and hedge funds.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.